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Abstract
Background: Bacterial vaginosis (BV) is a common condition that is associated with preterm birth
and acquisition of complex communities of vaginal bacteria that include several fastidious species.
Treatment of BV in pregnancy has mixed effects on the risk of preterm delivery, which some
hypothesize is due to variable antibiotic efficacy for the fastidious bacteria. Both oral and
intravaginal metronidazole can be used to treat bacterial vaginosis in pregnancy, but little is known
about the impact of different routes of antibiotic administration on concentrations of fastidious
vaginal bacteria.
Methods: This was a sub-study of a larger randomized trial of oral versus vaginal metronidazole
for treatment of BV in pregnancy. Fifty-three women were evaluated, including 30 women who
received oral metronidazole and 23 who received intravaginal metronidazole. Bacterial taxon-
specific quantitative PCR assays were used to measure concentrations of bacterial vaginosis
associated bacterium (BVAB) 1, 2, and 3, Gardnerella vaginalis, Atopobium species, Leptotrichia/
Sneathia  species,  Megasphaera  species, and Lactobacillus crispatus before and after antibiotic
treatment.
Results:  Concentrations of Leptotrichia  and  Sneathia  spp. and the fastidious Clostridia-like
bacterium designated BVAB1 decreased significantly with oral (p = .002, p = .02) but not vaginal
therapy (p = .141, p = .126). The fastidious bacterium BVAB3 did not significantly decrease with
either treatment. Concentrations of Atopobium spp., reportedly resistant to metronidazole in vitro,
dropped significantly with oral (p = .002) and vaginal (p = .001) treatment. There was no significant
difference in the magnitude of change in bacterial concentrations between oral and vaginal
treatment arms for any of the bacterial species. Lactobacillus crispatus concentrations did not
change.
Conclusion: Both oral and vaginal metronidazole therapy in pregnant women result in a significant
decrease in concentrations of most BV-associated anaerobic bacteria, with the exception that
Leptotrichia, Sneathia and BVAB1 do not significantly decrease with vaginal metronidazole therapy.
These data suggest that the route of antibiotic administration has a minor impact on bacterial
eradication in pregnant women with BV.
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Background
Bacterial vaginosis (BV) is a common cause of vaginal dis-
charge, with a prevalence of 29% in the general popula-
tion[1]. BV is characterized by a loss of the normal,
hydrogen peroxide (H2O2)-producing vaginal lactobacilli
and an increase in the presence of anaerobic bacteria. The
sequelae of BV can be serious; pregnant women with BV
diagnosed between 8 and 17 weeks gestation have up to a
sevenfold increase in the risk of delivery prior to 37
weeks[2].
The efficacy of oral metronidazole for treatment of BV has
been reported to range from 87–92% when evaluated 4
weeks after treatment, compared to 61–94% for vaginal
metronidazole[3]. However, recurrence rates as high as
70% have been noted one year after treatment[4]. In
women with a history of preterm delivery some studies
show a decreased risk of preterm delivery after screening
for and treatment of BV in early pregnancy[5]. In low risk
women, however, no change in the risk of preterm deliv-
ery was seen[6].
Recently, bacterial identification using broad range 16S
rRNA gene PCR has demonstrated that the vaginal micro-
biota in subjects with BV is more complex than has been
revealed by cultivation methods [7-9]. Not only is BV het-
erogeneous, with different populations and concentra-
tions of bacteria in different individuals, but previously
uncultivated bacteria are highly prevalent in women with
BV. Since these bacteria are difficult to culture, their sus-
ceptibility to antibiotics is not known at this time. Most
treatment studies in pregnancy have used oral metronida-
zole, though vaginal metronidazole is an acceptable
option [10,3] that has shown efficacy against fastidious
bacteria[11]. One hypothesis for the lack of effect of met-
ronidazole treatment on rates of preterm delivery is that
the route of antibiotic delivery may affect treatment effi-
cacy for some vaginal bacteria. For instance, oral delivery
of metronidazole may not eradicate some fastidious BV-
associated bacteria if oral treatment results in lower vagi-
nal antibiotic concentrations. To explore this hypothesis,
we evaluated vaginal fluid samples from a randomized
trial of oral versus vaginal metronidazole to examine the
effect of each formulation on quantities of fastidious BV-
associated bacteria.
Methods
This study analyzed samples collected during a prospec-
tive randomized trial comparing cure of BV with vaginal
versus oral metronidazole treatment for asymptomatic
bacterial vaginosis in early pregnancy that was conducted
between May 2000 and September 2004 in Seattle, Wash-
ington. Women were eligible for the parent study if they
had a singleton, live, intrauterine pregnancy between 10–
20 weeks, were able to provide informed consent and
were diagnosed with bacterial vaginosis by Nugent's Gram
stain criteria[12] at a screening visit. For this substudy, we
enriched our sample set for women likely to experience
poor response to treatment by selecting all women who
delivered preterm (< 37 weeks). We then selected 3 addi-
tional women who delivered at term, matched for race
and treatment arm, for each woman who delivered pre-
term (Figure 1). The parent study and this substudy were
approved by the University of Washington Institutional
Review Board (IRB); the parent study was also approved
by the Centers for Disease Control and Prevention IRB
and was registered with http://www.clinicaltrials.gov,
#NCT00153517.
Women were screened at an antenatal clinic visit, then
randomized to either oral metronidazole 250 mg three
times a day for 7 days with a vaginal placebo, or to 0.5 g
of 0.75% vaginal metronidazole twice a day with an oral
placebo. Women were assessed at 4 weeks and 8 weeks
after treatment, and at delivery. Data on Amsel's clinical
criteria for BV [13] were collected at baseline and at all fol-
low-up visits. At each visit four vaginal swabs were col-
This paper reports results of a nested case-control sub-study  of women who were participants in a randomized controlled  trial of oral versus vaginal metronidazole treatment for bac- terial vaginosis in the first trimester of pregnancy Figure 1
This paper reports results of a nested case-control 
sub-study of women who were participants in a rand-
omized controlled trial of oral versus vaginal metro-
nidazole treatment for bacterial vaginosis in the first 
trimester of pregnancy. This flow diagram shows how 
sub-study cases (women with preterm delivery) and controls 
(women with term delivery) were chosen from parent study 
groups randomized to oral or vaginal metronidazole treat-
ment, with reasons for subject exclusion.BMC Infectious Diseases 2009, 9:89 http://www.biomedcentral.com/1471-2334/9/89
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lected using standard Dacron swabs: one used for repeat
Gram stain, and three others that were placed in 900 uL of
phosphate buffered saline or normal saline and frozen at
-80°C.
Frozen vaginal swabs from the randomization visit and
one post-treatment visit were thawed, mixed by vortex
shaker for 1 minute and then removed from the liquid.
The liquid was centrifuged for 10 minutes at > 10,000 × g,
and the supernatant removed. The remaining pellet
underwent DNA extraction with the MoBio UltraClean
Soil DNA Isolation Kit (MoBio, Carlsbad, CA). A clean
swab was run through the DNA extraction process as an
extraction control for each set of samples. All extracted
DNA was tested in a quantitative PCR using primers tar-
geting the human 18S rRNA gene to validate that success-
ful DNA extraction occurred. An internal amplification
control PCR using exogenous DNA from a jellyfish gene
was used to test for presence of PCR inhibitors[14].
Vaginal fluid samples were then subjected to eight sepa-
rate taxon-directed 16S rRNA gene quantitative PCR
assays for the detection and quantification of individual
bacteria which have been described elsewhere [11]. One
assay detects two bacterial species (Leptotrichia  and
Sneathia) that are closely related. Each assay has previ-
ously been validated and proven to be sensitive (to a level
of 1–10 DNA copies/reaction) and specific (does not
detect other bacteria at a concentration of 106copies/rxn).
The assays use a TaqMan format, and are run on an ABI
7500 Thermocycler (Applied Biosystems, Foster City, CA).
Negative assays were assigned a value at the lower limit of
detection for that assay, and were included in all analyses,
including the calculation of mean bacterial concentra-
tions.
Statistical analysis was performed using SPSS version 11.
Demographic data was compared between groups using
the Chi-square test for categorical variables and the Mann-
Whitney U test for continuous variables. The change in
detection of bacteria (i.e. bacteria present pre-treatment
but not post-treatment) was evaluated using the Chi-
squared test. Bacterial concentrations were log trans-
formed and comparison of the mean difference in bacte-
rial concentrations before and after treatment within each
treatment group was performed using a paired T-test.
Comparison of mean log-transformed concentrations pre
and post-treatment between the two treatment groups, as
well as the change in concentration after treatment was
performed using an independent samples T-test. We esti-
mated that we would be able to detect a .95 log difference
in the mean change in concentrations of bacteria between
women randomized to oral verus vaginal treatment.
Results
In the parent study, 15 women delivered preterm (< 37
weeks gestation) and 14 had adequate samples for inclu-
sion in this sub-analysis. Forty-four women who delivered
at term, matched for treatment assignment and race were
selected. Of those, 4 did not have a complete set of pre
and post-treatment samples for analysis, and were
excluded. One additional subject who delivered at term
was excluded because no human rRNA gene DNA was
amplified from the post-treatment sample, suggesting that
DNA extraction was inadequate or the swab did not con-
tact a human surface. This left a total of 53 women in the
final population, 30 of whom had been randomized to
oral treatment (8 pre-term and 22 term deliveries) and 23
to vaginal treatment (6 pre-term and 17 term deliveries)
(Figure 1). Three women did not have samples available
from the 4-week follow-up visit, and so samples collected
8 weeks after treatment were analyzed. There were more
African American participants in the oral treatment group,
and more Hispanic participants in the vaginal treatment
group (Table 1). Women in the oral treatment group were
of higher gravidity, but the groups were otherwise similar
in terms of gestational age at enrollment and known risk
factors for BV, including smoking and douching.
At visit 1, the most prevalent bacteria detected included
Gardnerella vaginalis (98%), Atopobium spp. (73%) Megas-
phaera  (70%),  Leptotrichia/Sneathia  (55%) and BVAB2
(51%). Other bacteria were less common: BVAB1 (30%)
and BVAB3 (17%). Of women with bacteria detected,
there were no differences in rates of bacterial persistence
(defined as presence of the a bacterium in both the pre
and post-treatment samples) between the two treatment
groups (Table 2). Lactobacillus crispatus, a marker of vagi-
nal health, was rarely present either before or after treat-
ment (6/53 vs 9/53).
The decreases in concentrations of BVAB1 and Leptot-
richia/Sneathia were statistically significant in those sub-
jects receiving oral therapy, but not in the vaginal
treatment subgroup (Table 3). Neither oral nor vaginal
treatment caused a significant decrease in concentrations
of BVAB3. For the remaining bacteria, treatment was
highly effective at decreasing vaginal bacterial concentra-
tions (Table 3). Concentrations of Atopobium spp
decreased by a mean of 1.92 log (p < .01) in the oral group
and 2.12 log (p < .01) in the vaginal group, which was not
statistically significantly different. When pre and post-
treatment bacterial concentrations were compared
between treatment groups, no significant differences were
found.  Lactobacillus crispatus concentrations were not
affected by treatment.BMC Infectious Diseases 2009, 9:89 http://www.biomedcentral.com/1471-2334/9/89
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Discussion
Overall this study shows that oral and vaginal metronida-
zole treatment of bacterial vaginosis in early pregnancy
produces comparable changes in most BV-associated bac-
teria, even fastidious species. A few species, such as Leptot-
richia/Sneathia  and the bacterium BVAB1, show greater
response to oral than vaginal treatment. Concentrations
of the novel, fastidious bacterium BVAB3 did not decrease
significantly in either treatment arm, but this may be due
to the small numbers of women with detectable BVAB3 at
the first visit: only 6 women in the oral treatment arm and
3 in the vaginal treatment arm.
Subjects with BV have complex communities of vaginal
bacteria. Some bacterial species may be directly killed by
metronidazole. Other bacterial species may not be suscep-
tible to metronidazole but decrease in concentration
because they are metabolically dependent on other spe-
cies that are susceptible (indirect effects). These data dem-
onstrate that oral metronidazole therapy results in
decreased vaginal concentrations of all of these BVABs,
though the change in BVAB3 concentration was not statis-
tically significant. None of the fastidious BVAB increased
in concentration to suggest that they are resistant to the
direct or indirect effects of metronidazole. Atopobium spp
also showed a significant decrease in bacterial concentra-
tions after treatment despite the observation that many
Atopobium species are resistant to metronidazole in vitro,
suggesting an indirect effect [15]. Lactobacillus crispatus
concentrations did not rise significantly at 4 weeks after
treatment.
Table 1: Demographic data for women randomized to oral or vaginal metronidazole.
Oral treatment
(n = 30)
Vaginal treatment
(n = 23)
P valuea
Age (mean years) 23 20 .17
Raceb < .01
White 7 (20%) 7 (30%)
African American 13 (43%) 4 (17%)
Asian/PI 10 (33%) 4 (17%)
Hispanic 0 7 (30%)
Marital statusc .60
Single 12 (40%) 8 (35%)
Married/living with 17 (57%) 15 (65%)
Occupationc .65
Student 7 (23%) 8 (35%)
Employed 13 (43%) 8 (35%)
Unemployed 10 (33%) 7 (30%)
Education (highest completed)c .20
Primary 9 (30%) 10 (43%)
Secondary 12 (40%) 4 (17%)
Tertiary 9 (30%) 9 (39%)
History of douching 6 (20%) 2 (9%) .44
Smoker 11 (37%) 11 (48%) .41
Gravidity (median) 2 1 .02
Gestational age at enrollment (median in weeks) 15 16 .51
Gestational age at delivery (median in weeks) 39 40 .78
Birthweight (mean in grams) 3160.5 3203 .94
Clinical cure after treatment
(ie. 0 Amsel's criteria)
17 (57%) 14 (61%) .73
Microbiologic cure after treatment (ie. Nugent score ≤ 3) 16 (53%) 12 (52%) .58
aCategorical variables were analyzed using Chi square or Fisher's exact test. Continuous variables were analyzed using the Mann-Whitney U test.
bPercentages may not add up to 100% because of rounding, or missing data points
cMissing data for some participants
Table 2: Persistent detection of individual bacteria by species-
specific qPCR after treatment with oral or vaginal 
metronidazole (Chi-square test)
Bacteria Oral n/N (%) Vaginal n/N (%) P value
Gardnerella vaginalis 24/30 (80%) 16/22 (73%) .43
Megasphaera spp. 12/22 (55%) 5/15 (33%) .38
Leptotrichia/Sneathia 6/18 (33%) 5/11 (45%) .76
Atopobium vaginae 11/21 (52%) 9/17 (53%) .85
BVAB1 0/11 (0%) 1/5 (20%) .29
BVAB2 3/18 (17%) 1/9 (11%) .30
BVAB3 1/6 (17%) 1/3 (33%) .66
n = number of women with bacteria detected at visit 2
N = number of women with bacteria detected at visit 1BMC Infectious Diseases 2009, 9:89 http://www.biomedcentral.com/1471-2334/9/89
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One limitation of this study is that the post-treatment
sample was collected between 4–8 weeks after therapy
and may not reflect immediate (and possibly more dra-
matic) treatment response, though we would expect this
to have biased our study not to find a significant change
in concentrations. A second limitation is that given the
variation in the composition of bacterial populations
between women we did not have adequate power to ade-
quately assess the effect of treatment on BVAB3. Our study
quantified 8 individual bacterial species. Characterization
of total bacterial load and concentrations of additional
species would likely provide additional insight into how
different communities of vaginal bacteria change in
response to antibiotic therapy for BV.
There are many questions that remain unanswered,
including whether the intravaginal concentrations of
these bacteria reflect their prevalence in the upper genital
tract as well, and whether different routes of antibiotic
administration alter risk of preterm birth by affecting bac-
teria in different compartments. With a larger study pop-
ulation we would enhance our ability to determine if a
difference in response to treatment for any single bacte-
rium is associated with preterm birth.
Several interesting hypotheses can be generated from
these data. First, the lack of significant increase in Lactoba-
cillus crispatus concentrations 4 weeks after treatment for
BV suggests that the return of normal flora is slow, and
that women may be vulnerable to relapse due to the low
levels of protective lactobacilli. Second, the significant
decrease in Atopobium concentrations despite this organ-
ism's suspected resistance to metronidazole may suggest
that this bacterium and others require the presence of
other bacteria in order to thrive in the vaginal environ-
ment. Third, although Leptotrichia, Sneathia and BVAB1
species did not experience the same significant decrease in
concentration with vaginal as compared to oral treatment,
there was no difference in cure rates, nor in persistence of
the bacteria after treatment between the groups. This sug-
gests that the community of anaerobes may be more
important than the specific members and that targeting
keystone members of the microbial community may have
indirect effects on non-target or "antibiotic resistant" bac-
teria such as Atopobium vaginae.
Conclusion
Both oral and vaginal metronidazole therapy in pregnant
women result in a significant decrease in concentrations
of most BV-associated anaerobic bacteria, with the excep-
tion that Leptotrichia, Sneathia and BVAB1 do not signifi-
cantly decrease with vaginal metronidazole therapy. These
data suggest that the route of antibiotic administration
has a minor impact on bacterial eradication in pregnant
women with BV.
Table 3: Comparison of the pre- and post-treatment mean log10 
transformed bacterial concentrations and mean log10 – 
transformed change in concentration within the groups of 
women treated with oral and vaginal metronidazole.
Bacteria Oral (n = 30) Vaginal (n = 23)
L. crispatus Pre 1.409 ± 1.120a 1.495 ± 1.354
Post 1.798 ± 2.056 2.338 ± 2.726
Change .375
(p = .43b)
.843
(p = .17)
G. vaginalis Pre 6.939 ± 1.577 6.421 ± 1.962
Post 5.085 ± 2.449 4.372 ± 2.720
Change -1.853
(p < .01)
-2.049
(p < .01)
Megasphaera spp. Pre 4.883 ± 2.551 4.587 ± 2.812
Post 3.250 ± 2.834 1.970 ± 1.994
Change -1.633
(p < .01)
-2.617
(p < .01)
Leptotrichia/Sneathia Pre 3.588 ± 2.203 3.211 ± 2.456
Post 2.105+2.124 2.331+2.339
Change -1.484
(p < .01)
-.880
(p = .14)
Atopobium Pre 4.869 ± 2.567 4.715 ± 2.558
Post 3.000 ± 2.628 2.598 ± 2.270
Change -1.921
(p < .01)
-2.117
(p < .01)
BVAB1 Pre 2.714 ± 2.699 1.909 ± 2.100
Post 1.337 ± 1.340 1.355 ± 1.321
Change -1.378
(p = .026)
-.555
(.127)
BVAB2 Pre 3.343 ± 2.050 2.761 ± 2.294
Post 1.601 ± 1.603 1.207 ± .992
Change -1.742
(p < .01)
-1.554
(p < .01)
BVAB3 Pre 1.773+1.589 1.532 ± 1.447
Post 1.255 ± .976 1.144 ± .690
Change -1.459
(p = .12)
-.765
(p = .10)
aAll pre- and post-treatment values were compared between groups 
and were not significantly different.
bAll p-values are for paired T-test comparing pre-treatment 
concentration of bacterium to post-treatment concentration of 
bacterium within the individual treatment group.Publish with BioMed Central    and   every 
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